RESUMO
PURPOSE: Isoniazid, a first-line antitubercular drug, is associated with nervous system adverse drug reactions such as seizures, peripheral neuropathy, and psychosis. This systematic review of case reports and case series aimed to characterize the demographic, social, and clinical factors associated with isoniazid-induced psychosis in patients with active tuberculosis (TB) and those who received isoniazid for latent TB infection (LTBI). METHODS: We comprehensively searched the Embase, PubMed, and Scopus databases to identify relevant studies published between the date of inception of the database and June 2024. RESULTS: A total of 28 studies, including 21 case reports and 7 case series involved 37 patients who developed isoniazid-induced psychosis. A higher frequency of isoniazid-induced psychosis was observed during the first 2 months of treatment, with a relatively early onset observed among patients aged 18 years or less. Delusions and/or hallucinations are the common symptoms of isoniazid-induced psychosis. Psychomotor disturbances, disorganized speech or formal thought disorder, disorganized or abnormal behaviour, and neuropsychiatric symptoms (sleep disturbances, hostility or aggression, confusion, affective symptoms, anxiety symptoms, and cognitive difficulties) were the other symptoms observed in the included studies. More than 80% of cases rechallenged with isoniazid resulted in the recurrence of psychotic symptoms. CONCLUSION: Patients with TB and LTBI should be assessed for psychotic and neuropsychiatric symptoms during isoniazid therapy, mainly in the first 2 months. Further research is required to understand the impact of underlying risk factors, such as genetic predisposition and isoniazid pharmacokinetics, as well as the clinical utility and dosage recommendations of pyridoxine for managing isoniazid-induced psychosis.
RESUMO
PURPOSE: Significant pharmacokinetic variabilities have been reported for isoniazid across various populations. We aimed to summarize population pharmacokinetic studies of isoniazid in tuberculosis (TB) patients with a specific focus on the influence of N-acetyltransferase 2 (NAT2) genotype/single-nucleotide polymorphism (SNP) on clearance of isoniazid. METHODS: A systematic search was conducted in PubMed and Embase for articles published in the English language from inception till February 2022 to identify population pharmacokinetic (PopPK) studies of isoniazid. Studies were included if patient population had TB and received isoniazid therapy, non-linear mixed effects modelling, and parametric approach was used for building isoniazid PopPK model and NAT2 genotype/SNP was tested as a covariate for model development. RESULTS: A total of 12 articles were identified from PubMed, Embase, and hand searching of articles. Isoniazid disposition was described using a two-compartment model with first-order absorption and linear elimination in most of the studies. Significant covariates influencing the pharmacokinetics of isoniazid were NAT2 genotype, body weight, lean body weight, body mass index, fat-free mass, efavirenz, formulation, CD4 cell count, and gender. Majority of studies conducted in adult TB population have reported a twofold or threefold increase in isoniazid clearance for NAT2 rapid acetylators compared to slow acetylators. CONCLUSION: The variability in disposition of isoniazid can be majorly attributed to NAT2 genotype. This results in a trimodal clearance pattern with a multi-fold increase in clearance of NAT2 rapid acetylators compared to slow acetylators. Further studies exploring the generalizability/adaptability of developed PopPK models in different clinical settings are required.
Assuntos
Arilamina N-Acetiltransferase , Tuberculose , Adulto , Humanos , Antituberculosos/farmacocinética , Antituberculosos/uso terapêutico , Arilamina N-Acetiltransferase/genética , Peso Corporal , Genótipo , Isoniazida/farmacocinética , Isoniazida/uso terapêutico , Polimorfismo de Nucleotídeo Único , Tuberculose/tratamento farmacológico , Tuberculose/genéticaRESUMO
BACKGROUND: Isoniazid-induced pancreatitis is a potentially serious adverse drug reaction, however, the frequency of its occurrence is unknown. We conducted a systematic review to explore this adverse drug reaction comprehensively. METHODS: We performed an advanced search in PubMed, Web of Science, Scopus, Ovid, and Embase for studies that reported isoniazid-induced pancreatitis. From the extracted data of eligible cases, we performed a descriptive analysis and a methodological risk of bias assessment using a standardized tool. RESULTS: We included 16 case reports from eight countries comprising 16 patients in our systematic review. Most of the isoniazid-induced pancreatitis cases were extrapulmonary tuberculosis cases. We found the mean age across all case reports was 36.7 years. In all the cases, discontinuation of isoniazid resulted in the resolution of pancreatitis. CONCLUSIONS: We found the latency period for isoniazid-induced pancreatitis to be ranged from 12 to 45 days after initiation of isoniazid therapy. A low threshold for screening of pancreatitis by measuring pancreatic enzymes in patients on isoniazid presenting with acute abdominal pain is recommended. This would facilitate an early diagnosis and discontinuation of isoniazid, thus reducing the severity of pancreatitis and preventing the complications of pancreatitis.
Assuntos
Antituberculosos , Isoniazida , Pancreatite , Humanos , Isoniazida/efeitos adversos , Antituberculosos/efeitos adversos , Pancreatite/induzido quimicamente , Feminino , Adulto , Tuberculose/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Adulto Jovem , Adolescente , Fatores de Tempo , IdosoRESUMO
BACKGROUND AND AIM: Albuminuria in Diabetes mellitus (DM) patients may lead to nephropathy and end-stage renal disease. Our study aimed to assess the prevalence of albuminuria and its associated predictors among type 2 DM patients in the United Arab Emirates. METHODS: A retrospective cross-sectional study was conducted among type 2 DM patients in the diabetic clinic, Fujairah Hospital from 1st January 2016 to 30th January 2020 after getting the ethical clearance. Data were collected electronically from the health information system and analyzed using SPSS version 26. Regression analysis and ANOVA were used for inferential analysis. A P-value of ≤0.05 has been considered significant. RESULTS: Among the 200 patients included in the study, the mean age of the study population was 56 years and the majority of them were females (71%). The prevalence of albuminuria was found to be 44%. By using regression analysis, glycated hemoglobin (HbA1c; P=0.038) and systolic blood pressure (SBP; P=0.003) were found to be predictors of albuminuria. One way ANOVA revealed that there were significant associations between the albumin levels and HbA1c (P=0.004), SBP (P= 0.002), diastolic blood pressure (DBP; P=0.028), serum creatinine (Scr) (P=0.039), and glomerular filtration rate (GFR; P=0.013). CONCLUSION: To the best of our knowledge, this is the first study from Fujairah emirate that explored the prevalence and predictors of albuminuria in type 2 DM patients. We found a high prevalence of albuminuria among type 2 DM patients. HbA1c and SBP were directly contributing to albuminuria. To improve glycemic control, patients need to improve physical activity, reduce overweight and, adherence to medications that improve overall therapeutic outcome.
RESUMO
UNLABELLED: Pharmacogenomics is the branch of pharmacology which deals with the influence of genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with a drug's efficacy or toxicity. It aims to develop rational means to optimize drug therapy, with respect to the patients genotype, to ensure maximum efficacy with minimal adverse effects. Such approaches promise the advent of personalized medicine, in which drugs and drug combinations are optimized for each individual's unique genetic makeup. Pharmacogenomics is the whole genome application of pharmacogenetics, which examines the single gene interactions with drugs. KEYWORDS: Pharmacogenetics; Single nucleotide polymorphisms; Genomics; Genotype.